A Trial Investigating CDK4/6 Inhibitors for the Treatment of Mantle Cell Lymphoma
Selina Chen-Kiang, PhD, a professor of pathology and immunology at Weill Cornell Medical College, discusses the rationale of her phase I trial investigating the use of CDK4/6 inhibitors for the treatment of patients with mantle cell lymphoma.
Selina Chen-Kiang, PhD, a professor of pathology and immunology at Weill Cornell Medical College, discusses the rationale of her phase I trial investigating the use of CDK4/6 inhibitors for the treatment of patients with mantle cell lymphoma.
Chen-Kiang says the important part of using a CDK4/6 inhibitor is using combination therapies. For her trial, patients received a treatment combination of a CDK-4/6 inhibitor, palbociclib (Ibrance), plus the BTK inhibitor ibrutinib (Imbruvica).
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
